跳至主要内容
临床试验/ISRCTN11364482
ISRCTN11364482已完成未知

IMPACCT: IMmune Profiling of ICU pAtients to address Chronic Critical illness and ensure healThy ageing

Imperial College London0 个研究点目标入组 600 人开始时间: 2020年9月24日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
600

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

性别
All

入选标准

  • 1. Age =18 years
  • 2. Admitted to an ICU for =48 hours and <120 hours (5 days)
  • 3. Being (or has been) treated for suspected sepsis during this ICU admission:
  • 3.1. Intravenous antibiotics to treat a known / suspected infection
  • 3.2. Acute organ dysfunction
  • 4. Has received organ support (any of the following):
  • 4.1. Respiratory – any form of mechanical ventilation, non-invasive ventilation or high-flow nasal oxygen for =24h, OR
  • 4.2. Cardiovascular – any intravenous continuous infusion of vasopressor or inotrope for =24h, OR
  • 4.3. Renal – any form of continuous renal replacement therapy for =24 or acute and new intermittent haemodialysis with at least two episodes
  • 5. Is expected to require ongoing care in an environment capable of providing organ support (eg and ICU or HDU) for at least one more calendar day

排除标准

  • 1. Severe neutropenia (neutrophil count <0.5 x 10(9)/L) due to an underlying disease / treatment (but not sepsis)
  • 2. Corticosteroids (intravenously or oral) of more than an equivalent dose of prednisolone 0.1mg/kg for at least 7 days within the past 30 days (not as part of sepsis management)
  • 3. Use of therapeutic antibodies during this admission
  • 4. Onco-haematological disease (eg, lymphoma, leukaemia, myeloma) treated within the 5 years before inclusion
  • 5. Allogenic hematopoietic stem cell transplantation (regardless of timing)
  • 6. Chemotherapy or immunotherapy within the last 6 months prior to inclusion date
  • 7. Innate immune deficiency (eg, severe combined immunodeficiency)
  • 8. Acquired immune deficiency (eg HIV or AIDS, any stage)
  • 9. Receiving any other immunosuppressive therapy (eg anti-TNF therapies)
  • 10. Patients with a ‘withdrawal of life-sustaining treatment’ decision, at time of inclusion
  • 11. Moribund and not expected to survive 24 hours
  • 12. Participation in an interventional study of immunomodulating therapy or any other unlicensed therapy
  • 13. Pregnant or breastfeeding women
  • 14. No social security insurance (France only)
  • 15. Patients with restricted liberty, prisoners or under legal protection
  • 16. Previously enrolled in IMPACCT

研究者

相似试验